A. D. Beadell Investment Counsel Inc. Has $4.58 Million Position in Johnson & Johnson (JNJ)
A. D. Beadell Investment Counsel Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 6.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,222 shares of the company’s stock after selling 2,568 shares during the period. Johnson & Johnson makes up approximately 3.9% of A. D. Beadell Investment Counsel Inc.’s holdings, making the stock its 2nd biggest position. A. D. Beadell Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $4,579,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in JNJ. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth about $124,000. Institutional investors own 65.70% of the company’s stock.
Johnson & Johnson (NYSE JNJ) opened at $141.71 on Friday. Johnson & Johnson has a one year low of $110.76 and a one year high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market cap of $380,710.00, a P/E ratio of 24.60, a PEG ratio of 2.65 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the prior year, the business earned $1.68 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.37%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
Several research firms have issued reports on JNJ. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.40 target price on the stock in a research note on Monday, January 1st. JPMorgan Chase & Co. cut shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday. Citigroup began coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 target price on the stock. BMO Capital Markets restated a “positive” rating and set a $152.00 target price (up previously from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Finally, Jefferies Group upped their target price on shares of Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $145.52.
ILLEGAL ACTIVITY NOTICE: “A. D. Beadell Investment Counsel Inc. Has $4.58 Million Position in Johnson & Johnson (JNJ)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/a-d-beadell-investment-counsel-inc-has-4-58-million-position-in-johnson-johnson-jnj/1796945.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.